Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Drug Updates

Michele D. Kaufman, PharmD, BSc, RPh  |  Issue: September 2013  |  September 1, 2013


Michele Kaufman is a freelance medical writer based in New York City, a pharmacist at New York Presbyterian–Lower Manhattan Hospital, and adjunct faculty at Touro College of Pharmacy.

References

  1. FDA advisor panel votes against new use of AbbVie’s Humira. Published July 23, 2013. www.reuters.com/article/2013/07/23/us-fda-arthritis-humira-idUSBRE96M0PV20130723. Accessed August 1, 2013.
  2. Dearment A. FDA approves Zubsolv for the maintenance treatment of opioid dependence. Published July 4, 2013. www.orexo.com/en/Investor-Relations/Press-releases/ ?guid=788294. Accessed August 1, 2013.
  3. FDA panel narrowly backs new use of UCB’s arthritis drug. Published July 23, 2013. www.reuters.com/article/2013/07/23/us-ucb-fda-idUSBRE96M11S20130723. Accessed July 24, 2013.
  4. Dennis M. Novartis’ Sandoz unit starts late-stage trial of biosimilar version of Amgen’s Enbrel. Published June 24, 2013. www.firstwordpharma.com/node/1111986#axzz2ar2peBl0. Accessed June 24, 2013.
  5. Walsh N. IV Simponi Aria OK’d for arthritis. Published July 19, 2013. www.medpagetoday.com/Rheumatology/Arthritis/40580. Accessed August 1, 2013.
  6. DeArment A. Actavis’ generic version of Opana ER wins FDA approval. Published July 12, 2013. http://ir.actavis.com/phoenix.zhtml?c=65778&p=irol-newsArticle&ID=1837442. Accessed August 1, 2013.
  7. Fischer A. Brisdelle (paroxetine) approval for menopausal vasomotor symptoms (hot flashes) and warning update on concomitant use with tamoxifen. Published June 28, 2013. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm359030.htm. Accessed August 1, 2013.
  8. US FDA accepts Iroko Pharma’s NDA filing of lower dose submicron indomethacin to treat mild to moderate acute pain in adults. Published July 18, 2013. www.pharmabiz.com/NewsDetails.aspx?aid=76546&sid=2. Accessed August 1, 2013.
  9. FDA Drug Safety Communication: FDA warns of rare but serious skin reactions with the pain reliever/fever reducer acetaminophen. Published August 1, 2013. www.fda.gov/downloads/Drugs/DrugSafety/UCM363052.pdf. Accessed August 1, 2013.
  10. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. Published July 26, 2013. www.fda.gov/Drugs/DrugSafety/ucm362415.htm. Accessed July 26, 2013.
  11. Actemra (tocilizumab) injection: Safety label changes. Published April 2013. www.fda.gov/Safety/MedWatch/SafetyInformation/ucm352022.htm. Accessed August 1, 2013.
  12. Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013;173:754-761.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Drug Updates Tagged with:acetaminophenadalimumabDrugsFDASafety

Related Articles

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Drug Updates

    September 1, 2009

    Information on New Approvals and Medication Safety

    Drug UPDATES

    March 18, 2011

    Information on New Approvals and Medication Safety

    Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death

    June 8, 2016

    In a clinical trial, patients with osteoarthritis taking low-dose SoluMatrix meloxicam used less rescue medication to manage pain. Also, the FDA has issued a new warning against using oral ketoconazole off label to treat onychomycosis and fungal skin infections…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences